Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors
05 janv. 2023 07h30 HE
|
Sensei Biotherapeutics
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer,...
Sensei Biotherapeutics Provides Update on Strategic Priorities
08 déc. 2022 07h30 HE
|
Sensei Biotherapeutics
- Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses -- Continued focus on development of TMAb™ programs; IND submission for lead antibody...
Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
22 nov. 2022 07h30 HE
|
Sensei Biotherapeutics
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...
Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody
21 nov. 2022 07h30 HE
|
Sensei Biotherapeutics
BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...
Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
10 nov. 2022 09h00 HE
|
Sensei Biotherapeutics
- SNS-101, a highly pH-selective antibody to VISTA, demonstrated anti-tumor effects and promising pharmacokinetic properties in preclinical studies - - Characterization of endogenous expression...
Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
08 nov. 2022 07h30 HE
|
Sensei Biotherapeutics
- Recent SNS-101 preclinical data demonstrate a favorable pharmacokinetic profile, evidence of advanced anti-tumor effects and a superior cytokine release profile - - New preclinical data on multiple...
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, “Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint”
07 nov. 2022 07h30 HE
|
Sensei Biotherapeutics
Featuring Dr. Robert Schreiber, globally recognized expert on the immune system’s role in anti-cancer immunity Pre-registration available for live event, to be held November 21, 2022, at 2:15 p.m....
Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference
02 nov. 2022 07h30 HE
|
Sensei Biotherapeutics
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
05 oct. 2022 08h05 HE
|
Sensei Biotherapeutics
BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer,...
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
30 sept. 2022 16h05 HE
|
Sensei Biotherapeutics
- SNS-101 demonstrated a favorable pharmacokinetic profile, enhanced anti-tumor effects in combination with anti-PD-1 antibodies and a significantly improved cytokine release profile as compared to a...